Therefore, blocking the activity of the adenosinergic pathway to inhibit the production of Ado, as well as its signaling to induce the production of TGF-β and the subsequent expression of PD-L1 in the TME, could contribute to improving the design of combinatorial therapies against CeCa and other types of cancer. The gene discussed is CD274; the disease is cancer.